☰

David J. Riese, Ph.D. - Publications

Affiliations: 
1997-2010 Medicinal Chemistry and Molecular Pharmacology Purdue University, West Lafayette, IN, United States 
 2010- Drug Discovery and Development Auburn University, Auburn, AL, United States 
Area:
Cancer Cell Biology, Molecular Biology, and Pharmacology; Cancer Drug Discovery
Website:
http://www.auburn.edu/academic/pharmacy/directory/david-riese.html
Tree Info Similar researchers PubMed Report error

56 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Cullum RL, Ghosh T, Lucas L, Waits D, Riese D. Abstract 2144: Mutations in ERBB4 may account for clinical resistance of melanomas to inhibitors of the RAS/RAF/MEK/MAPK pathway Cancer Research. 79: 2144-2144. DOI: 10.1158/1538-7445.Sabcs18-2144  0.8
2018 Cullum RL, Lucas LM, Piazza JT, Senfeld JI, Neel LT, Gupta RB, David AE, Riese DJ. Abstract A159: Characterization of putative ErbB4 antagonists: targeted melanoma drug discovery Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A159  0.84
2017 Cullum RL, Piazza JT, Senfeld JI, Neel LT, Gupta RB, David AE, Riese DJ. Abstract 1245: Screening methodologies for the discovery of small molecule melanoma therapeutics targeted at the ErbB4 receptor tyrosine kinase Cancer Research. 77: 1245-1245. DOI: 10.1158/1538-7445.Am2017-1245  0.831
2016 Cullum R, David A, Riese DJ. Abstract 1353: Validation and implementation of screens for partial agonists and antagonists of the ErbB4/HER4 receptor tyrosine kinase: Targeted melanona drug discovery Cancer Research. 76: 1353-1353. DOI: 10.1158/1538-7445.Am2016-1353  0.841
2015 Kanthala S, Mill CP, Riese DJ, Jaiswal M, Jois S. Expression And Purification Of HER2 Extracellular Domain Proteins In Schneider2 Insect Cells. Protein Expression and Purification. PMID 26363121 DOI: 10.1016/J.Pep.2015.09.001  0.818
2015 Cullum RL, Gupta RB, Riese DJ. Abstract B17: A high-throughput screening process for the discovery of melanoma chemotherapeutics targeted at the ErbB4 receptor tyrosine kinase Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-B17  0.844
2014 Riese DJ, Cullum RL. Epiregulin: roles in normal physiology and cancer. Seminars in Cell & Developmental Biology. 28: 49-56. PMID 24631357 DOI: 10.1016/J.Semcdb.2014.03.005  0.839
2013 Gallo RM, Bryant IN, Mill CP, Kaverman S, Riese DJ. Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant. Journal of Cancer Research and Therapeutic Oncology. 1: 10. PMID 24791013 DOI: 10.17303/Jcrto.2013.1.104  0.844
2013 Allen RE, Copeland J, Franks AS, Karimi R, McCollum M, Riese DJ, Lin AY. Team-based learning in US colleges and schools of pharmacy. American Journal of Pharmaceutical Education. 77: 115. PMID 23966718 DOI: 10.5688/Ajpe776115  0.591
2013 Nickerson NK, Mill CP, Wu HJ, Riese DJ, Foley J. Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo. Oncology Research. 20: 303-17. PMID 23879171 DOI: 10.3727/096504013X13639794277761  0.828
2013 Schmerge JD, Riese DJ, Hasiotis ST. Vinegaroon (arachnida: Thelyphonida: Thelyphonidae) trackway production and morphology: Implications for media and moisture control on trackway morphology and a proposal for a novel system of interpreting arthropod trace fossils Palaios. 28: 116-128. DOI: 10.2110/Palo.2012.P12-012R  0.552
2012 Foley J, Nickerson N, Riese DJ, Hollenhorst PC, Lorch G, Foley AM. At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. Odontology / the Society of the Nippon Dental University. 100: 109-29. PMID 22684584 DOI: 10.1007/S10266-012-0070-5  0.735
2012 Wilson KJ, Mill C, Lambert S, Buchman J, Wilson TR, Hernandez-Gordillo V, Gallo RM, Ades LM, Settleman J, Riese DJ. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors (Chur, Switzerland). 30: 107-16. PMID 22260327 DOI: 10.3109/08977194.2011.649918  0.84
2012 Wilson KJ, Mill CP, Gallo RM, Cameron EM, VanBrocklin H, Settleman J, Riese DJ. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist. The Biochemical Journal. 443: 133-44. PMID 22216880 DOI: 10.1042/Bj20110921  0.844
2011 Mill CP, Zordan MD, Rothenberg SM, Settleman J, Leary JF, Riese DJ. ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer. Genes & Cancer. 2: 792-804. PMID 22393464 DOI: 10.1177/1947601911431080  0.849
2011 Zordan MD, Mill CP, Riese DJ, Leary JF. A high throughput, interactive imaging, bright-field wound healing assay. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 79: 227-32. PMID 22045642 DOI: 10.1002/Cyto.A.21029  0.737
2011 Riese DJ. Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery? Expert Opinion On Drug Discovery. 6: 185-193. PMID 21532939 DOI: 10.1517/17460441.2011.547468  0.715
2011 Mill CP, Gettinger KL, Riese DJ. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Experimental Cell Research. 317: 392-404. PMID 21110957 DOI: 10.1016/J.Yexcr.2010.11.007  0.844
2011 Riese DJ, Hasiotis ST, Odier GP. Synapsid burrows and associated trace fossils in the Lower Jurassic Navajo Sandstone, southeastern Utah, U.S.A., indicates a diverse community living in a wet desert ecosystem Journal of Sedimentary Research. 81: 299-325. DOI: 10.2110/Jsr.2011.25  0.554
2010 Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP, Riese DJ. EGFR signaling in breast cancer: bad to the bone. Seminars in Cell & Developmental Biology. 21: 951-60. PMID 20813200 DOI: 10.1016/J.Semcdb.2010.08.009  0.847
2009 Mill CP, Chester JA, Riese DJ. EGFR may couple moderate alcohol consumption to increased breast cancer risk. Breast Cancer (Dove Medical Press). 1: 31-8. PMID 24367161  0.804
2009 Gilmore JL, Gonterman RM, Menon K, Lorch G, Riese DJ, Robling A, Foley J. Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone. Molecular Cancer Research : McR. 7: 1714-28. PMID 19825997 DOI: 10.1158/1541-7786.Mcr-09-0131  0.833
2009 Coon BG, Mukherjee D, Hanna CB, Riese DJ, Lowe M, Aguilar RC. Lowe syndrome patient fibroblasts display Ocrl1-specific cell migration defects that cannot be rescued by the homologous Inpp5b phosphatase. Human Molecular Genetics. 18: 4478-91. PMID 19700499 DOI: 10.1093/Hmg/Ddp407  0.658
2009 Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacology & Therapeutics. 122: 1-8. PMID 19135477 DOI: 10.1016/J.Pharmthera.2008.11.008  0.832
2009 Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ. Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 19: 138-46. PMID 19028082 DOI: 10.1016/J.Euroneuro.2008.10.002  0.66
2009 Willmarth NE, Baillo A, Dziubinski ML, Wilson K, Riese DJ, Ethier SP. Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cellular Signalling. 21: 212-9. PMID 18951974 DOI: 10.1016/J.Cellsig.2008.10.003  0.813
2009 Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ, de Cremoux P, Stenvang J, Lykkesfeldt AE. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Research and Treatment. 114: 263-75. PMID 18409071 DOI: 10.1007/S10549-008-0011-8  0.755
2008 Rothenberg SM, Engelman JA, Le S, Riese DJ, Haber DA, Settleman J. Modeling oncogene addiction using RNA interference. Proceedings of the National Academy of Sciences of the United States of America. 105: 12480-4. PMID 18711136 DOI: 10.1073/Pnas.0803217105  0.831
2008 Gilmore JL, Scott JA, Bouizar Z, Robling A, Pitfield SE, Riese DJ, Foley J. Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Research and Treatment. 110: 493-505. PMID 17882547 DOI: 10.1007/S10549-007-9748-8  0.818
2007 Gallo RM, Riese DJ. The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056. Growth Factors (Chur, Switzerland). 25: 329-33. PMID 18236211 DOI: 10.1080/08977190701804008  0.792
2007 Wilson KJ, Mill CP, Cameron EM, Hobbs SS, Hammer RP, Riese DJ. Inter-conversion of neuregulin2 full and partial agonists for ErbB4. Biochemical and Biophysical Research Communications. 364: 351-7. PMID 17945187 DOI: 10.1016/J.Bbrc.2007.10.004  0.798
2007 Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ, Settleman J, Haber DA. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Research. 67: 7319-26. PMID 17671201 DOI: 10.1158/0008-5472.Can-06-4625  0.826
2007 Riese DJ, Gallo RM, Settleman J. Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 29: 558-65. PMID 17508401 DOI: 10.1002/Bies.20582  0.846
2006 Pitfield SE, Bryant I, Penington DJ, Park G, Riese DJ. Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. Oncology Research. 16: 179-93. PMID 17120616 DOI: 10.3727/000000006783981134  0.789
2006 Gallo RM, Bryant I, Fry R, Williams EE, Riese DJ. Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. Biochemical and Biophysical Research Communications. 349: 372-82. PMID 16934755 DOI: 10.1016/J.Bbrc.2006.08.055  0.816
2006 Gilmore JL, Gallo RM, Riese DJ. The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events. The Biochemical Journal. 396: 79-88. PMID 16445385 DOI: 10.1042/Bj20051687  0.834
2005 Hobbs SS, Gallo RM, Riese DJ. Phe45 of NRG2beta is critical for the affinity of NRG2beta for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2beta*. Growth Factors (Chur, Switzerland). 23: 273-83. PMID 16338790 DOI: 10.1080/08977190500199345  0.839
2005 VanBrocklin HF, Lim JK, Coffing SL, Hom DL, Negash K, Ono MY, Gilmore JL, Bryant I, Riese DJ. Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. Journal of Medicinal Chemistry. 48: 7445-56. PMID 16279804 DOI: 10.1021/jm050607w  0.836
2004 Gilmore JL, Riese DJ. secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation. Oncology Research. 14: 589-602. PMID 15667000 DOI: 10.3727/0965040042707907  0.83
2004 Hobbs SS, Cameron EM, Hammer RP, Le AT, Gallo RM, Blommel EN, Coffing SL, Chang H, Riese DJ. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene. 23: 883-93. PMID 14661053 DOI: 10.1038/Sj.Onc.1207250  0.855
2003 Williams EE, Trout LJ, Gallo RM, Pitfield SE, Bryant I, Penington DJ, Riese DJ. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Letters. 192: 67-74. PMID 12637154 DOI: 10.1016/S0304-3835(02)00690-0  0.8
2002 Walker-Daniels J, Riese DJ, Kinch MS. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Molecular Cancer Research : McR. 1: 79-87. PMID 12496371  0.697
2002 Hobbs SS, Coffing SL, Le AT, Cameron EM, Williams EE, Andrew M, Blommel EN, Hammer RP, Chang H, Riese DJ. Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene. 21: 8442-52. PMID 12466964 DOI: 10.1038/Sj.Onc.1205960  0.841
2002 Penington DJ, Bryant I, Riese DJ. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 13: 247-56. PMID 12114214  0.846
2002 Feroz K, Williams E, Riese DJ. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation. Cellular Signalling. 14: 793-8. PMID 12034361 DOI: 10.1016/S0898-6568(02)00019-0  0.787
2001 Mu F, Coffing SL, Riese DJ, Geahlen RL, Verdier-Pinard P, Hamel TE, Johnson J, Cushman M. Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization. Journal of Medicinal Chemistry. 44: 441-52. PMID 11462983 DOI: 10.1021/Jm000387G  0.728
2000 Sweeney C, Lai C, Riese DJ, Diamonti AJ, Cantley LC, Carraway KL. Ligand discrimination in signaling through an ErbB4 receptor homodimer. The Journal of Biological Chemistry. 275: 19803-7. PMID 10867024 DOI: 10.1074/Jbc.C901015199  0.783
1998 Riese DJ, Komurasaki T, Plowman GD, Stern DF. Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. The Journal of Biological Chemistry. 273: 11288-94. PMID 9556621 DOI: 10.1074/Jbc.273.18.11288  0.815
1998 Riese DJ, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 20: 41-8. PMID 9504046 DOI: 10.1002/(Sici)1521-1878(199801)20:1<41::Aid-Bies7>3.0.Co;2-V  0.798
1997 Chang H, Riese DJ, Gilbert W, Stern DF, McMahan UJ. Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature. 387: 509-12. PMID 9168114 DOI: 10.1038/387509A0  0.799
1997 Kannan S, De Santis M, Lohmeyer M, Riese DJ, Smith GH, Hynes N, Seno M, Brandt R, Bianco C, Persico G, Kenney N, Normanno N, Martinez-Lacaci I, Ciardiello F, Stern DF, et al. Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. The Journal of Biological Chemistry. 272: 3330-5. PMID 9013573 DOI: 10.1074/Jbc.272.6.3330  0.809
1996 Riese DJ, Kim ED, Elenius K, Buckley S, Klagsbrun M, Plowman GD, Stern DF. The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4. The Journal of Biological Chemistry. 271: 20047-52. PMID 8702723 DOI: 10.1074/Jbc.271.33.20047  0.806
1995 Riese DJ, van Raaij TM, Plowman GD, Andrews GC, Stern DF. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Molecular and Cellular Biology. 15: 5770-6. PMID 7565730 DOI: 10.1128/Mcb.15.10.5770  0.806
1993 Hwang ES, Riese DJ, Settleman J, Nilson LA, Honig J, Flynn S, DiMaio D. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. Journal of Virology. 67: 3720-9. PMID 8389903 DOI: 10.1128/Jvi.67.7.3720-3729.1993  0.77
1991 Leptak C, Ramon y Cajal S, Kulke R, Horwitz BH, Riese DJ, Dotto GP, DiMaio D. Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16. Journal of Virology. 65: 7078-83. PMID 1658398 DOI: 10.1128/Jvi.65.12.7078-7083.1991  0.72
1990 Riese DJ, Settleman J, Neary K, DiMaio D. Bovine papillomavirus E2 repressor mutant displays a high-copy-number phenotype and enhanced transforming activity. Journal of Virology. 64: 944-9. PMID 2153255 DOI: 10.1128/Jvi.64.2.944-949.1990  0.778
Show low-probability matches.